COVID-19 Outcomes in Lung Transplant Recipients Following Pre-Exposure Prophylaxis With Tixagevimab-Cilgavimab During the Omicron BA.5 Surge : A Single Center Analysis
Copyright © 2024 Demolder, Schaevers, Lagrou, De Munter, Beeckmans, Verleden, Godinas, Dupont, Van Bleyenbergh, Lorent and Vos..
Lung transplant (LTx) recipients are at high risk for COVID-19 related morbidity and mortality. Data regarding pre-exposure prophylaxis (PrEP) with tixagevimab-cilgavimab in this population are scarce. We therefore evaluated COVID-19 breakthrough infections and COVID-19 related complications after PrEP in a retrospective single-center study, including 264 LTx recipients who received PrEP between June 2022 and December 2022, when Omicron BA.5 was the dominant circulating SARS-CoV-2 variant. PrEP was indicated for fully vaccinated patients with poor seroconversion (anti-S <260 BAU/mL). COVID-19 breakthrough infection after PrEP occurred in 11.0% within the first 3 months, increasing to 17.4% within 6 months. Hospitalization rate rose from 27.6% to 52.9% (p = 0.046), while ICU admissions and COVID-19 mortality remained low, respectively occurring in 6.5% and 4.3% of patients with breakthrough infection within 6 months. COVID-19 breakthrough infection and associated hospitalization remained an important problem during the Omicron BA.5 surge in fully vaccinated LTx recipients with deficient seroconversion, despite PrEP with tixagevimab-cilgavimab. However, ICU admissions and COVID-19 mortality were low. Waning of neutralizing effects of PrEP and changing circulating SARS-CoV-2 variants may explain increases in COVID-19 infections and hospitalizations over time after PrEP, highlighting the need for novel, long-term effective PrEP strategies in these high-risk patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Transplant international : official journal of the European Society for Organ Transplantation - 37(2024) vom: 04., Seite 12061 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Demolder, Saartje [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
1KUR4BN70F |
|---|
| Anmerkungen: |
Date Completed 09.02.2024 Date Revised 07.03.2024 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.3389/ti.2024.12061 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368178528 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368178528 | ||
| 003 | DE-627 | ||
| 005 | 20240307232314.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240208s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/ti.2024.12061 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1319.xml |
| 035 | |a (DE-627)NLM368178528 | ||
| 035 | |a (NLM)38328617 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Demolder, Saartje |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 Outcomes in Lung Transplant Recipients Following Pre-Exposure Prophylaxis With Tixagevimab-Cilgavimab During the Omicron BA.5 Surge |b A Single Center Analysis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.02.2024 | ||
| 500 | |a Date Revised 07.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Demolder, Schaevers, Lagrou, De Munter, Beeckmans, Verleden, Godinas, Dupont, Van Bleyenbergh, Lorent and Vos. | ||
| 520 | |a Lung transplant (LTx) recipients are at high risk for COVID-19 related morbidity and mortality. Data regarding pre-exposure prophylaxis (PrEP) with tixagevimab-cilgavimab in this population are scarce. We therefore evaluated COVID-19 breakthrough infections and COVID-19 related complications after PrEP in a retrospective single-center study, including 264 LTx recipients who received PrEP between June 2022 and December 2022, when Omicron BA.5 was the dominant circulating SARS-CoV-2 variant. PrEP was indicated for fully vaccinated patients with poor seroconversion (anti-S <260 BAU/mL). COVID-19 breakthrough infection after PrEP occurred in 11.0% within the first 3 months, increasing to 17.4% within 6 months. Hospitalization rate rose from 27.6% to 52.9% (p = 0.046), while ICU admissions and COVID-19 mortality remained low, respectively occurring in 6.5% and 4.3% of patients with breakthrough infection within 6 months. COVID-19 breakthrough infection and associated hospitalization remained an important problem during the Omicron BA.5 surge in fully vaccinated LTx recipients with deficient seroconversion, despite PrEP with tixagevimab-cilgavimab. However, ICU admissions and COVID-19 mortality were low. Waning of neutralizing effects of PrEP and changing circulating SARS-CoV-2 variants may explain increases in COVID-19 infections and hospitalizations over time after PrEP, highlighting the need for novel, long-term effective PrEP strategies in these high-risk patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a lung transplantation | |
| 650 | 4 | |a outcome predictors | |
| 650 | 4 | |a pre-exposure prophylaxis | |
| 650 | 4 | |a tixagevimab-cilgavimab | |
| 650 | 7 | |a tixagevimab |2 NLM | |
| 650 | 7 | |a cilgavimab |2 NLM | |
| 650 | 7 | |a 1KUR4BN70F |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 700 | 1 | |a Schaevers, Veronique |e verfasserin |4 aut | |
| 700 | 1 | |a Lagrou, Katrien |e verfasserin |4 aut | |
| 700 | 1 | |a De Munter, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Beeckmans, Hanne |e verfasserin |4 aut | |
| 700 | 1 | |a Verleden, Geert M |e verfasserin |4 aut | |
| 700 | 1 | |a Godinas, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Dupont, Lieven J |e verfasserin |4 aut | |
| 700 | 1 | |a Van Bleyenbergh, Pascal |e verfasserin |4 aut | |
| 700 | 1 | |a Lorent, Natalie |e verfasserin |4 aut | |
| 700 | 1 | |a Vos, Robin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Transplant international : official journal of the European Society for Organ Transplantation |d 1992 |g 37(2024) vom: 04., Seite 12061 |w (DE-627)NLM012972258 |x 1432-2277 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2024 |g day:04 |g pages:12061 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/ti.2024.12061 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2024 |b 04 |h 12061 | ||